PCSK9 inhibitors are being studied for various uses, including treating hyperlipidemia and potentially improving outcomes in cancer patients on immunotherapy. Research is also exploring their role in primary prevention for high-risk patients and their comparison to statins in terms of effectiveness and risk. The use of PCSK9 inhibitors appears to be evolving, with studies examining trends in patient access and utilization, as well as their potential benefits in acute coronary syndrome.